Cargando…
Neurodevelopmental outcomes following intravitreal bevacizumab injection in Japanese preterm infants with type 1 retinopathy of prematurity
PURPOSE: The purpose of this study was to evaluate neurodevelopmental outcomes in 18-month old (corrected age) preterm infants who received an intravitreal bevacizumab (IVB) injection for the treatment of type 1 retinopathy of prematurity (ROP). METHODS: In this ten-year retrospective study, we revi...
Autores principales: | Arima, Mitsuru, Akiyama, Masato, Fujiwara, Kohta, Mori, Yujiro, Inoue, Hirosuke, Seki, Eiko, Nakama, Takahito, Tsukamoto, Shoko, Ochiai, Masayuki, Ohga, Shouichi, Sonoda, Koh-Hei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7083318/ https://www.ncbi.nlm.nih.gov/pubmed/32196539 http://dx.doi.org/10.1371/journal.pone.0230678 |
Ejemplares similares
-
Late-onset Circulatory Collapse and Continuous Positive Airway Pressure are Useful Predictors of Treatment-requiring Retinopathy of Prematurity: A 9-year Retrospective Analysis
por: Arima, Mitsuru, et al.
Publicado: (2017) -
Involution of retinopathy of prematurity and neurodevelopmental outcomes after intravitreal bevacizumab treatment
por: Chang, Yu-Shan, et al.
Publicado: (2019) -
Gastrointestinal symptoms as an extended clinical feature of Pierson syndrome: a case report and review of the literature
por: Nishiyama, Kei, et al.
Publicado: (2020) -
Rhodopsin-positive cell production by intravitreal injection of small molecule compounds in mouse models of retinal degeneration
por: Fujii, Yuya, et al.
Publicado: (2023) -
Study protocol for a multicentre, open-label, single-arm phase I/II trial to evaluate the safety and efficacy of ripasudil 0.4% eye drops for retinopathy of prematurity
por: Arima, Mitsuru, et al.
Publicado: (2021)